Organigram Completes Investigation and Provides Update on Compensation Policy

Denis Arsenault, Organigram’s Chief Executive Officer, oversaw an extensive investigation that ultimately resulted in inconclusive findings with no hard evidence leading to the source of the contamination discovered. However, as a result of the contamination issue, the company has instituted a series of new protocols to prevent a reoccurrence of any issue of this nature. “We are determined to never have this happen again,” said Arsenault. “The inquiry was thorough and was undertaken with the full cooperation and assistance of Health Canada and outside experts.” 

Seven new company-wide initiatives have now been implemented. They are: 

1. Effective since January 1, 2017, Organigram tests every product lot for pesticides before they are made available for sale; 

2. All inputs from outside suppliers are now tested before they are used. Inputs include such things as seeds, growing medium, fertilizers, water, etc.; 

3. The company has updated its Integrated Pest Management (IPM) operating procedures to include periodic live plant sampling for pesticide screening; 

4. The company has developed a formal program for receiving, securing and testing critical inputs on a routine basis; 

5. A new, comprehensive screening process is now in place to pre-qualify suppliers before they are approved to do business with Organigram; 

6. The company has installed closed-circuit cameras in areas of its facility that were previously not required to be monitored; 

7. The company has developed and instituted a new education and training regime for all employees. 




Arsenault also announced changes to the Company’s compensation plan for uninsured clients impacted by the recall. Organigram will now provide all clients without insurance coverage a full credit for their affected purchases. Details about this credit will be communicated directly to each client. The total value of these credits represents approximately $2.26M and will be reflected in the company’s Q2 results scheduled for publication in April 2017. 

“Since the January recall, testing of harvested crops has been more comprehensive and effective -- no trace of any contaminant has been detected,” said Arsenault. “As well, the company is undergoing a recertification process with Ecocert, the organization that validates our organic standards. Ecocert suspended -- but did not remove -- our certification during the investigation, and has been fully supportive of our efforts to bring operations back to full compliance with the organization’s standards,” Arsenault continues. 

The well-being and satisfaction of former, existing, and future clients remains a top priority of the Company. “We are working extremely hard to regain the faith and trust of our clients,” he concluded. 

For more information, visit 

For further information, please contact:

Organigram Holdings Inc. 
Larry Rogers 
Chief Operating Officer 
(506) 801-3567 


Organigram Holdings Inc. 
Giselle Doiron 
Director of Investor and Media Relations 
(506) 801-8986 

Have a question for us?

Call 1-844-644-4726 (1-844-OGI-GRAM) and the folks on our client support team like Dan, Janice and Jeff can answer any question you have.

Monday to Thursday: 8:30 AM to 8:00 PM 
Friday: 8:30 AM to 6:30 PM 
Fax: 1-855-267-1386

Stay informed. #DiscoverOGI.

Interested in keeping up with Organigram news? Subscribe to our mailing lists and stay up-to-date on Organigram products, patient programs, company news and investor relations. 

By signing up, I acknowledge that I can unsubscribe at any time, and I accept the terms, conditions and privacy policy.

If you wish to receive newsletters from Organigram Holdings Inc. and its subsidiaries, please provide your email address and click on the “Subscribe” button above. If we do not receive your consent, we may be unable to send you communications. If you have any questions, or if you wish to withdraw your consent at any time, please feel free to contact us by phone at 1-844-644-4726 or by email at By clicking “Subscribe” I consent to receipt of communications as indicated above.